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Background
A pediatric HIV-1 vaccine is required to protect infants
against HIV-1 transmission from breastfeeding. Such a vac-
cine would need to induce protective immunity at mucosal
surfaces in neonates as soon as possible after birth. Recom-
binant adenovirus (rAd) vectors have been shown to elicit
potent systemic and mucosal virus-specific immune
responses in adult non-human primates and humans but
have not previously been studied in detail in infants.
Methods
Newborn rhesus monkeys were injected intramuscular
(i.m.) with 10^11 viral particles of rAd serotype 26 or
35 vectors expressing SIVmac239 Gag. Peripheral blood
was collected to determine systemic Gag-specific cellular
and humoral immune responses. At week 52, peripheral
lymph nodes, bronchoalveolar lavage (BAL) and pinch
biopsies of colorectal, duodenal and oral cavity mucosa
were collected to evaluate mucosal Gag-specific
T lymphocyte responses.
Results
A single injection of rAd26 encoding SIVmac239 Gag in
rhesus monkeys on the day of birth elicited detectable
SIV-specific cellular immune responses, but these
responses were transient and waned quickly. In contrast,
an accelerated heterologous prime-boost regimen invol-
ving administration of rAd35 at birth and rAd26 at
4 weeks of life elicited potent and durable Gag-specific
cellular and humoral immune responses in neonatal
rhesus monkeys, including mucosal responses that
remained detectable at one year of age.
Conclusion
These results suggest the potential of an accelerated
heterologous rAd prime-boost regimen as a candidate
neonatal HIV-1 vaccine in newborns.
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